Centiva Capital LP Decreases Position in AxoGen, Inc. (NASDAQ:AXGN)

Centiva Capital LP reduced its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 11.7% in the 3rd quarter, Holdings Channel.com reports. The firm owned 26,871 shares of the medical equipment provider’s stock after selling 3,555 shares during the period. Centiva Capital LP’s holdings in AxoGen were worth $377,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Quest Partners LLC raised its stake in AxoGen by 23,066.7% during the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 2,076 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of AxoGen during the third quarter worth about $56,000. Koss Olinger Consulting LLC acquired a new position in shares of AxoGen during the second quarter worth about $75,000. Oppenheimer & Co. Inc. acquired a new position in shares of AxoGen during the third quarter worth about $156,000. Finally, Quantbot Technologies LP purchased a new stake in AxoGen during the third quarter worth about $165,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Price Performance

Shares of AXGN stock opened at $14.67 on Tuesday. The company has a market capitalization of $645.63 million, a PE ratio of -45.84 and a beta of 1.06. The firm has a fifty day simple moving average of $13.76 and a 200-day simple moving average of $11.28. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. AxoGen, Inc. has a twelve month low of $5.55 and a twelve month high of $15.90.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $15.00.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.